Skip to main content

Advertisement

SpringerLink
Log in

Genetic variants in IL-17A rs10484879 and serum levels of IL-17A are associated with psoriasis risk

  • Original Paper
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

Psoriasis is an inflammatory skin disease characterized by keratinocyte hyperproliferation with effective environmental and genetic factors. Recent studies showing that the IL-23/IL-17 axis plays a central role in the pathogenesis of the disease. Experimental and clinical studies suggest that IL-17A, an important regulatory effector cytokine in this pathway and triggers changes mainly in affected tissues. Based on the central role of IL-17A in the pathogenesis of psoriasis, we thought that variations in this gene could affect the susceptibility and severity of this disease. Therefore, in this study, we aimed to analyze whether IL-17A rs10484879 variant has an effect on psoriasis pathogenesis in Turkish population. In this case–control study, the study group consisting of 564 patient (188 psoriasis patients (66 males/122 females)/376 controls (132 males/244 females) and they were genotyped in terms of IL-17A (rs10484879) polymorphism with TaqMan 5 'Allelic Discrimination Test. IL-17A serum levels were measured with the Enzyme-linked immunosorbent assay (ELISA). The genotype distributions of the IL-17A rs10484879 polymorphism between the patient and control groups were statistically different in the TT genotype and it was observed more commonly in the patient group compared to the controls (p < 0.001). Similarly, the T allele was observed with a higher prevalence in the patient group compared to the controls (p = 0.007). IL-17A serum levels were associated with increased serum concentration, respectively, TT > GT > GG in all study groups (p < 0.05). We would like to report that IL-17A rs10484879 TT genotype and T allele are associated with increased risk of psoriasis in the Turkish population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Boehncke WH, Schön MP (2015) Psoriasis. Lancet 5:983–994

    Article  Google Scholar 

  2. Nestle FO, Kaplan DH, Barker J (2009) Psoriasis. N Engl J Med 361:496–509

    Article  CAS  Google Scholar 

  3. Andrew B, Andrea C (2018) The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol 55:379–390

    Article  Google Scholar 

  4. Lowes MA, Suárez-Fariñas M, Krueger JG (2014) Immunology of psoriasis. Annu Rev Immunol 32:227–255

    Article  CAS  Google Scholar 

  5. Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M et al (2011) Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 131:677–687

    Article  CAS  Google Scholar 

  6. Martin DA, Towne JE, Kricorian G et al (2013) The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol 133:17–26

    Article  CAS  Google Scholar 

  7. Chiricozzi A, Suárez-Fariñas M, Fuentes-Duculan J et al (2016) Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris. Br J Dermatol 174:136–145

    Article  CAS  Google Scholar 

  8. Belasco J, Louie JS, Gulati N et al (2015) Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis. Arthritis Rheumatol 67:934–944

    Article  CAS  Google Scholar 

  9. Caproni M, Antiga E, Melani L et al (2009) Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol 29:210–214

    Article  CAS  Google Scholar 

  10. Ortega C, Fernandez AS, Carrillo JM et al (2009) IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukocyte Biol 86:435–443

    Article  CAS  Google Scholar 

  11. Chiricozzi A, Nograles KE, Johnson-Huang LM et al (2014) L-17 induces an expanded range of downstream genes in reconstituted human epidermis model. PLoS ONE. https://doi.org/10.1371/journal.pone.0090284

    Article  PubMed  PubMed Central  Google Scholar 

  12. Nograles KE, Zaba LC, Guttman-Yassky E et al (2008) Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 159:1092–1102

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Harper EG, Guo C, Rizzo H et al (2009) Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol 129:2175–2183

    Article  CAS  Google Scholar 

  14. Lande R, Botti E, Jandus C et al (2014) The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun 5:5621

    Article  CAS  Google Scholar 

  15. Krueger JG (2015) An autoimmune “attack” on melanocytes triggers psoriasis and cellular hyperplasia. J Exp Med 212:2186

    Article  CAS  Google Scholar 

  16. Arakawa A, Siewert K, Stöhr J et al (2015) Melanocyte antigen triggers autoimmunity in human psoriasis. J Exp Med 212:2203–2212

    Article  Google Scholar 

  17. Verstrepen L, Carpentier I, Verhelst K et al (2009) A20 binding inhibitors of NF-kappa B and apoptosis signaling. Biochem Pharmacol 15:105–114

    Article  Google Scholar 

  18. Gaffen SL (2009) Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 9:556–567

    Article  CAS  Google Scholar 

  19. Langley RG, Elewski BE, Lebwohl M et al (2014) Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med 371:326–338

    Article  Google Scholar 

  20. Hueber W, Patel DD, Dryja T et al (2010) Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 6:52ra72

    Google Scholar 

  21. Karen L, Smith MP, Thibodeaux Q et al (2019) Anti IL-17 in psoriasis. Expert Rev Clin Immunol 15:1185–1194

    Article  Google Scholar 

  22. Bissonnette R, Luger T, Thaçi D et al (2018) Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol 32:1507–1514

    Article  CAS  Google Scholar 

  23. Nast A, Amelunxen L, Augustin M et al (2018) Guideline for the treatment of psoriasis vulgaris, update—short version part 1—systemic treatment. J Dtsch Dermatol Ges 16:645–669

    PubMed  Google Scholar 

  24. World Medical Association (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310:2191–2194

    Article  Google Scholar 

  25. https://www.psychologie.hhu.de/arbeitsgruppen/allgemeine-psychologie-und-arbeitspsychologie/gpower

  26. Elder JT, Bruce AT, Gudjonsson JE et al (2010) Molecular dissection of psoriasis: integrating genetics and biology. J Invest Dermatol 130:1213–1226

    Article  CAS  Google Scholar 

  27. Krueger JG, Fretzin S, Suarez-Farinas M et al (2012) IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol 130:145

    Article  CAS  Google Scholar 

  28. Chiricozzi A, Romanelli P, Volpe E et al (2018) Scanning the immunopathogenesis of psoriasis. Int J Mol Sci 19:179

    Article  Google Scholar 

  29. Banuelos J, Cao Y, Shin SC, Lu NZ (2017) Immunopathology alters Th17 cell glucocorticoid sensitivity. Allergy 72:331–341

    Article  CAS  Google Scholar 

  30. Xu S, Cao X (2010) Interleukin-17 and its expanding biological functions. Cell Mol Immunol 7:164

    Article  CAS  Google Scholar 

  31. Diani M, Altomare G, Reali E (2016) T helper cell subsets in clinical manifestations of psoriasis. J Immunol Res. https://doi.org/10.1155/2016/7692024

    Article  PubMed  PubMed Central  Google Scholar 

  32. Giunta A, Ventura A, Chimenti MS et al (2017) Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy. Drug Des Dev Ther 11:1643–1651

    Article  CAS  Google Scholar 

  33. Białecka M, Ostasz R, Kurzawski M et al (2016) IL17A and IL17F gene polymorphism association with psoriasis risk and response to treatment in a Polish population. Dermatology 232:592–596

    Article  Google Scholar 

  34. Kim SY, Hur MS, Choi BG et al (2017) A preliminary study of new single polymorphisms in the T helper type 17 pathway for psoriasis in the Korean population. Clin Exp Immunol 187:251–258

    Article  CAS  Google Scholar 

  35. Batalla A, Coto E, González-Lara L et al (2015) Association between single nucleotide polymorphisms IL17RA rs4819554 and IL17E rs79877597 and Psoriasis in a Spanish cohort. J Dermatol Sci 80:111–155

    Article  CAS  Google Scholar 

  36. Rocío PP, Guillermo SL, Teresa C et al (2015) The polymorphism rs763780 in the IL-17F gene is associated with response to biological drugs in patients with psoriasis. Pharmacogenomics 16:1723–1731

    Article  Google Scholar 

  37. Rajinder K, Arun KR, Sunil K et al (2018) Association of genetic polymorphism of interleukin-17A and interleukin-17F with susceptibility of psoriasis. Indian J Med Res 148:422–426

    Article  Google Scholar 

  38. Silje MS, Lene FS, Marianne E et al (2018) Serum cytokine measurements and biological therapy of psoriasis—prospects for personalized treatment? Scand J Immunol. https://doi.org/10.1111/sji.12725

    Article  Google Scholar 

  39. Blauvelt A, Ferris LK, Yamauchi PS et al (2017) Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR). Br J Dermatol 177:1552–1561

    Article  CAS  Google Scholar 

  40. Teng MWL, Bowman EP, Elwe JJM et al (2015) IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med 21:719–729

    Article  CAS  Google Scholar 

  41. Branigan PJ, Liu X, Chen Y et al (2017) Guselkumab attenuates disease- and mechanism-related biomarkers in patients with moderate-to-severe plaque psoriasis. J Invest Dermatol 137:51

    Article  Google Scholar 

Download references

Acknowledgements

The present study was supported by a grant from the Scientific Research Projects Coordination Unit of Giresun University (Project No: SAĞ-BAP-A-270220-07).

Author information

Authors and Affiliations

  1. Department of Skin Diseases, Faculty of Medicine, Giresun University, Giresun, Turkey

    Burak Akşan

  2. Department of Medical Genetics, Faculty of Medicine, Giresun University, Giresun, Turkey

    Ayşegül Başak Akadam-Teker

Authors
  1. Burak Akşan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ayşegül Başak Akadam-Teker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ayşegül Başak Akadam-Teker.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Akşan, B., Akadam-Teker, A.B. Genetic variants in IL-17A rs10484879 and serum levels of IL-17A are associated with psoriasis risk. Arch Dermatol Res 314, 937–942 (2022). https://doi.org/10.1007/s00403-021-02308-w

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-021-02308-w

Keywords

Search

Navigation